annual cash & cash equivalents:
$258.30M+$55.35M(+27.27%)Summary
- As of today (September 16, 2025), TRML annual cash & cash equivalents is $258.30 million, with the most recent change of +$55.35 million (+27.27%) on December 31, 2024.
- During the last 3 years, TRML annual cash & cash equivalents has risen by +$14.33 million (+5.87%).
- TRML annual cash & cash equivalents is now at all-time high.
Performance
TRML Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$239.23M-$10.07M(-4.04%)Summary
- As of today (September 16, 2025), TRML quarterly cash & cash equivalents is $239.23 million, with the most recent change of -$10.07 million (-4.04%) on June 30, 2025.
- Over the past year, TRML quarterly cash & cash equivalents has dropped by -$50.30 million (-17.37%).
- TRML quarterly cash & cash equivalents is now -18.37% below its all-time high of $293.06 million, reached on March 31, 2024.
Performance
TRML quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TRML Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +27.3% | -17.4% |
| 3 y3 years | +5.9% | +15.5% |
| 5 y5 years | - | - |
TRML Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +3027.9% | -18.4% | +2797.0% |
| 5 y | 5-year | at high | +3027.9% | -18.4% | +2797.0% |
| alltime | all time | at high | +3027.9% | -18.4% | +2797.0% |
TRML Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $239.23M(-4.0%) |
| Mar 2025 | - | $249.31M(-3.5%) |
| Dec 2024 | $258.30M(+27.3%) | $258.30M(-8.4%) |
| Sep 2024 | - | $281.92M(-2.6%) |
| Jun 2024 | - | $289.53M(-1.2%) |
| Mar 2024 | - | $293.06M(+44.4%) |
| Dec 2023 | $202.95M(+2357.6%) | $202.95M(+38.0%) |
| Sep 2023 | - | $147.02M(-3.4%) |
| Jun 2023 | - | $152.25M(-8.2%) |
| Mar 2023 | - | $165.81M |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $8.26M(-96.6%) | - |
| Dec 2022 | - | $8.26M(-95.7%) |
| Sep 2022 | - | $193.87M(-6.4%) |
| Jun 2022 | - | $207.11M(-8.2%) |
| Mar 2022 | - | $225.53M(-7.6%) |
| Dec 2021 | $243.97M(+63.2%) | $243.97M(-4.2%) |
| Sep 2021 | - | $254.73M(-4.3%) |
| Jun 2021 | - | $266.22M(+90.0%) |
| Mar 2021 | - | $140.10M(-6.3%) |
| Dec 2020 | $149.49M | $149.49M |
FAQ
- What is Tourmaline Bio, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Tourmaline Bio, Inc.?
- What is Tourmaline Bio, Inc. annual cash & cash equivalents year-on-year change?
- What is Tourmaline Bio, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Tourmaline Bio, Inc.?
- What is Tourmaline Bio, Inc. quarterly cash & cash equivalents year-on-year change?
What is Tourmaline Bio, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of TRML is $258.30M
What is the all time high annual cash & cash equivalents for Tourmaline Bio, Inc.?
Tourmaline Bio, Inc. all-time high annual cash & cash equivalents is $258.30M
What is Tourmaline Bio, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, TRML annual cash & cash equivalents has changed by +$55.35M (+27.27%)
What is Tourmaline Bio, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of TRML is $239.23M
What is the all time high quarterly cash & cash equivalents for Tourmaline Bio, Inc.?
Tourmaline Bio, Inc. all-time high quarterly cash & cash equivalents is $293.06M
What is Tourmaline Bio, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, TRML quarterly cash & cash equivalents has changed by -$50.30M (-17.37%)